MESTO EDINOGO INGALYaTORA V TERAPII BRONKhIAL'NOY ASTMY: OBESPEChENIE DOSTIZhENIYa KONTROLYa


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Bronchial asthma (BA) refers to diseases, which can vary significantly depending on the environmental conditions, and these changes occurs for a minimum period of time. In this regard, the selection of BA therapy should be based on the need to achieve control of the disease. And it is important not only to achieve the control of BA, but also to continuously retain it. Treatment strategy for BA using single inhaler that allow controlling the disease and preventing the development of relapses in the future is considered. Symbicort (budesonide + formoterol) is a basic drug for the control of inflammation and, at the same time, for the immediate relief of BA symptoms.

Texto integral

Acesso é fechado

Sobre autores

N. Knyazheskaya

Bibliografia

  1. Global Initiative for Asthma. Global strategy for asthma management and prevention. Available from: www.ginasthma.org. Date last updated, 2006.
  2. Global Initiative for Asthma. Global strategy for asthma management and prevention. Available from: www. ginasthma.org. Date last updated, 2009.
  3. Kuehni CE, Frey U. Age-related differences in perceived asthma control in childhood: guidelines and reality. Eur Respir J 2002;20:880-89.
  4. Архипов В.В. Изменение объема терапии в зависимости от уровня контроля бронхиальной астмы// Consilium medicum 2007. Т. 9. № 1.
  5. Bateman ED, Reddel HK, Ericksson G, et al. Overall asthma control: the relationship between current control and future risk. J Allergy Clin Immunol 2010;125:600-8.
  6. Juniper EF, O'Byrne PM, Guyatt GH, et al. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999;14:902-7.
  7. Boulet L-P, Boulet V, Milot J. How should we quantify asthma control? A proposal. Chest 2002;122: 2217-23.
  8. Svensson K, Mork AC, Juniper EF. ACQ - is five out of seven items acceptable in large clinical studies? Qual Life Res 2003;12:771.
  9. Juniper EF, Svensson K, Mork AC, et al. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 2005;99:553-58.
  10. Juniper EF, Bousquet J, Abetz L et al. Identifying "well-controlled" and "not well-controlled" asthma using the Asthma Control Questionnaire. Respir Med 2006;100:616-21.
  11. Архипов В.В., Григорьева Е.В., Гавришина Е.В. Контроль над бронхиальной астмой в России: результаты многоцентрового наблюдательного исследования НИКА // Пульмонология 2011. № 6. С. 87-93.
  12. Edwards SJ, Gruffydd-Jones K, Ryan DP. Systematic review and meta-analysis of budesonide/formoterol in a single inhaler. Curr Med Res Opin 2007; 23:1809-20.
  13. Kuna P, Peters MJ, Buhl R. Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus a higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone. Abstract presented at the ERS Congress 2006.
  14. Rabe K, Atienza T, Magyar P, et al. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised, controlled, double-blind study. Lancet 2006;368:744-53.
  15. Vogelmeier C, D'Urzo A, Pauwels R, et al. Budesonide/ formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J 2005;26(5):819-28.
  16. Scicchitano R, Aalbers R, Ukena D, et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 2004;20(9): 140318.
  17. Rabe KF, Pizzichini E, Stallberg B, et al. Budesonide/ Formoterol in a Single Inhaler for Maintenance and Relief in Mild-to-Moderate Asthma: A Randomized, Double-Blind Trial. Chest 2006;129:246-56.
  18. Aalbers R, Backer V, Kava TTK, et al. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Curr Med Res Opin 2004;20(2):225
  19. Ankerst J, Persson G, Weibull E. A high dose of budesonide/formoterol in a single inhaler was well tolerated by asthmatic patients. Eur Respir J 2000; 16(Suppl. 31 ):33s + poster.
  20. Grimfeld A, et al. Longterm study of nebulised budesonide in young children with moderate to severe asthma. Eur Respir J 1994;7:27S.
  21. Derom E, Van Schoor J, Verhaeghe W, et al. Systemic Effects of Inhaled Fluticasone Propionate and Budesonide in Adult Patients with Asthma. Am J Respir. Crit Care Med 1999;160:157-61.
  22. Boorsma M, Andersson N, Larsson P, Ullman A. Assessment of the relative systemic potency of inhaled fluticasone and budesonide. Eur Respir J 1996;9(7):1427-32.
  23. Miller-Larsson A, Mattsson H, Hjertberg E, et al. Reversible fatty acid conjugation of budesonide. Novel Mechanism for Prolonged Retention of Topically Applied Steroid in Airway Tissue. Drug Metab Dispos 1998;26:623-30.
  24. Brattsand R, Miller-Larsson A. The role of intracellular esterification in budesonide once-daily dosing and airway selectivity. Clin Ther 2003;25:C28-41.
  25. Miller-Larsson A, Jansson P, Runstrnm A, Brattsand R. Prolonged Airway Activity and Improved Selectivity of Budesonide Possibly Due to Esterification. Am J Respir тов правильной технике ингаляции и предупредить об отсутствии вкусовых ощущений. Применение рассмотренного метода оказывает положительное влияние на качество жизни больных и способствует достижению долгосрочного контроля БА. Crit Care Med 2000; 162:1455-61.
  26. Foresi A, Morelli MC, Catena E. Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. Chest 2000;117:440-46.
  27. Anderson GP. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of highly potent and selective agonist bronchodilatator. Life Sci 1993;52(26):2145-60.
  28. Nials AT, Ball DI, Butchers PR, et al. Formoterol on airway smooth muscle and human lung mast cells: a comparison with salbutamol and salmeterol. Eur J Pharmacol 1994;251:127-35.
  29. Brambilla C, Le Gros V, Bourdeix I, et al. Formoterol 12 BID Administered via Single-Dose Dry Powder Inhaler in Adults with Asthma Suboptimally Controlled with Salmeterol or On-Demand Salbutamol: A Multicenter, Randomized, Open-Label, Parallel-Group Study. Clin Ther 2003;25(7):2022-36.
  30. Molimard M, Naline E, Zhang Y. Long- and short-adrenoreceptor agonists: interactions in human contracted bronchi. Eur Respir J 1998;11:583-58.
  31. O,Connor BJ, Alkinan SL, Barnes P.J. Tolerance to the non-bronchodilatator effects of inhaled ß2-agonists in asthma. N EnglJ Med 1992;327:1204-08.
  32. Politiek MJ, Boorsma M, Aalbers R. Comparison of formoterol, salbutamol and salmeterol in methacho-line-induced severe bronchoconstriction. Eur Respir J 1999;13:988-92.
  33. Tattersfield AE, Lofdahl C-G, Postma DS, et al. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised controlled trial. Lancet 2001;357:257-61.
  34. Pauwels RA, Sears NR, Cambell M, et al. Formoterol as relief medication in asthma: a world safety and effectiveness trial. Eur Respir J 2003;22:787-94.
  35. Hospenthal MA, Peter JI. Long-acting beta (2) - agonists in management of asthma exacerbation. Curr Opin Pulm Med 2005; 11:69-73.
  36. Demoly P, Louis R, Soes-Petersen U, et al. Budesonide/ formoterol maintenance and reliever therapy versus conventional best practice. Respir Med 2009;103:1623-32.
  37. Цой А.Н., Архипов В.В., Чапурин С.А., Чурилин Ю.Ю. Фармакоэкономическое исследование новой концепции применения Симбикорта у больных бронхиальной астмой // Пульмонология 2007. № 3. С. 34-40.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2013